Similar articles

• Adverse events related to muraglitazar use in diabetes.

  Parra D, Beckey C, Thomas T. Parra D, et al. JAMA. 2006 May 3;295(17):1997-8; author reply 1998. doi: 10.1001/jama.295.17.1997-b. JAMA. 2006. PMID: 16670403 No abstract available.
• Selling safety--lessons from muraglitazar.

  Brophy JM. Brophy JM. JAMA. 2005 Nov 23;294(20):2633-5. doi: 10.1001/jama.294.20.jed50074. Epub 2005 Oct 20. JAMA. 2005. PMID: 16239638 No abstract available.
• Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

  Nissen SE, Wolski K, Topol EJ. Nissen SE, et al. JAMA. 2005 Nov 23;294(20):2581-6. doi: 10.1001/jama.294.20.joc50147. Epub 2005 Oct 20. JAMA. 2005. PMID: 16239637
• The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.

  Kalliora C, Drosatos K. Kalliora C, et al. J Cardiovasc Pharmacol. 2020 Nov;76(5):514-526. doi: 10.1097/FJC.0000000000000891. J Cardiovasc Pharmacol. 2020. PMID: 33165133 Free PMC article. Review.
• Examining the safety of PPAR agonists - current trends and future prospects.

  Bortolini M, Wright MB, Bopst M, Balas B. Bortolini M, et al. Expert Opin Drug Saf. 2013 Jan;12(1):65-79. doi: 10.1517/14740338.2013.741585. Epub 2012 Nov 8. Expert Opin Drug Saf. 2013. PMID: 23134541 Review.